1Jager RD, Aiello LP, Patel SP, et al. Risks of intravitreous injection: a comprehensive review. Retina, 2004,24: 676-698.
2Rycroft B. Penicillin and the control of deep intraocular infection.Br J Ophthalmol, 1945,29:57-87.
3Yamashita T, Doi N, Sakamoto T. Weak symptoms of bacterial endophthalmitis after a triamcinolone acetonide-assisted pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol, 2004,242: 679-681.
4Sakamoto T, Enaida H, Kubota T, et al. Incidence of acute endophthalmitis after t riamcinolone-assisted Pars Plana Vitrectomy. Am J Ophthalmol, 2004,138:137-138.
5Forster RK, Zachary IG, Cottingham AJ, et al. Further observations on the diagnosis, cause, and treatment of endophthalmitis. Am J Ophthalmol, 1976,81: 52-56.
6Penfold PL, Gyory JF, Hunyor AB, et al. Exudative macular degeneration and intravitreal triamcinolone:a pilot study. Aust N ZJ Ophthalmol, 1995,23:293-298.
7Ip MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol, 2004,122:1131-1136.
8Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema:preliminary results of a prospective controlled trial.Ophthalmology, 2004,111: 218-224.
9Jonas JB, Harder B, Kamppeter BA. Inter-eye difference in diabetic macular edema after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol, 2004,138: 970-977.
10Audren F, Tod M, Massin P, et al. Pharmacokineticpharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci, 2004,45:3435-3441.
